Research & Development
Imprimis Pharmaceuticals Launches Programme to Ease Access to Compounded Ophthalmic Formulations
8 March 2018 - - San Diego, California-based ophthalmology-focused pharmaceutical company Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find and typically needed on an urgent basis, the company said.
The goal of this program is to provide high-quality compounded medications from an Imprimis FDA-inspected facility and ship it within 24-48 hours. Imprimis intends to make this program available in all 50 US states.
Physicians can order custom compounded formulations on an as needed basis for their patients.
Imprimis is dedicated to making high quality innovative medications accessible and affordable in all 50 states.
The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or spin-out companies.


Related Headlines